For diabetes-specific data, the completed TRANSCEND-T2D-1 trial (537 patients, 40 weeks) is the relevant source: retatrutide reduced HbA1c by up to 2.0% (9mg dose), with 8289% of patients reaching the 120 bpm at rest) The Unknowns: What We're Still Waiting to Learn Full 2-year published safety data: TRIUMPH-1 104-week extension data is available for the BMI 35 subgroup, but full publication of the complete 2-year dataset is pending expected late 2026
It was originally made as a drug to help treat certain skin conditions
[DOI] [PubMed] [Google Scholar] 58.Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, et al
The documented incidence of MTX-induced AKI varies between 1.8% and 38.6%, and this can be justified by the non-unified descriptions of acute kidney injury [6,7,8]